• Schedule An Appointment
  • (855) 528-7322
  • Career Openings
  • Español 中國傳統的 简体中文
  • Locations
  • Care Team
  • Locations
  • Care Team
    • All Doctors
    • Medical Oncologists
    • Radiation Oncologists
    • Breast Surgeons
    • Surgical Oncologist
    • Support/Palliative
    • Behavioral Health
    • Registered Dietitian Nutritionists
    • Our APPs
  • Patients
    • Accepted Insurance
    • Appointments
    • Blood Disorders
    • Cancers
    • Carespace Portal
    • Fill my Prescription
    • Make A Payment
    • Mammography
    • Medical Marijuana
    • Patient Advocacy
    • Physical Therapy
    • Radiology
  • Professionals
    • Patient Referral
    • Clinical Trials
    • Our Research Center
    • Our Research Team
    • Career Opportunities
    • News & Events
    • NCCN Guidelines
  • Research
    • About Research
    • Common Questions
    • Study Participation
    • Our Research Center
    • Our Research Team
    • Clinical Trials
  • About
    • About Us
    • News & Updates
    • Our Leadership
    • Our Difference
    • Our Friends
    • Our Services
      • Medical Oncology
      • Radiation Oncology
      • Hematology
      • Fill My Prescription
      • Physical Therapy
      • Health & Wellness
      • Laboratory Testing
      • Personalized Medicine
      • Diagnostic Imaging
      • Other Services
    • Career Opportunities
    • Newsletters

eNRGy: HER2xHER3 Bispecific Antibody MCLA-128 for the Treatment of an Advanced or Metastatic Solid Tumor Malignancy With a Documented NRG1 Fusion

Condition: Solid Tumors

Sponsor: Merus N.V.

Full Title
MCLA-128-CL01: A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors

Study Treatment
HER2xHER3 bispecific antibody MCLA-128

Eligibility/Info
Cohort F: Advanced or metastatic NRG1 fusion positive non-small cell lung cancer that has been treated with or is ineligible for available standard of care therapy
Cohort G: Advanced or metastatic NRG1 fusion positive pancreatic cancer that has been treated with or is ineligible for available standard of care therapy
Cohort H: Advanced or metastatic NRG1 fusion positive solid tumor that has been treated with or is ineligible for available standard of care therapy

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.


Go To Trial Homepage

Call Us

(855) 528-7322

Contact us today to request an appointment.

Virtual & Telemedicine available.

Request Appointment

Patient Links

  • Make An Appointment
  • Make A Payment
  • Fill My Prescription
  • Accepted Insurance
  • Medical Marijuana
  • Appointment Information
  • Physical Therapy
  • Patient Advocacy
  • Carespace Portal
  • Cancer Information

About

  • Our Story
  • Our Care Team
  • Locations
  • Careers & Job Openings
  • Newsletters
  • What Is Cancer?
  • What Are Blood Disorders?
  • What Is Oncology?
  • What Is Hematology?
  • Podcasts

Research

  • About Research
  • Common Questions
  • Study Participation
  • Our Research Center
  • Our Research Team
  • Clinical Trials
  • Observational Studies
  • Cancer Resources
  • Blood Disorder Resources

Contact Us


info@nycancer.com

  • Terms and Conditions
  • Privacy Policy
  • HIPAA and Compliance
  • Healthix
© 2023 NYCancer.com